BotaMedi Inc.

2011- Company renamed BotaMedi- Established a portfolio of a new paradigm, Seanol-based nutraceuticals and cosmeceuticals- Signed joint research agreement with Phloronol (San Francisco, CA) and 4 university medical centers (Stanford Univ., UCLA, UCSF, and USC) for drug development in CNS area- Carried out joint marketing project for Seanol-based products in collaboration with KT&G Group - Signed agreement with Kee Pharma (New Delhi, India) for distribution of Algaea-X to clinics in India2009- Developed a large open aquaculture technology for the raw material of Seanol- Signed agreement with Umeken (Japan) for distribution of Seanol in Japan 2010- Distributed Seanol to Healthy Direction (US) and 7 other US companies- Started botanical drug development in collaboration with Phloronol (San Francisco, CA)- Opened the 1st Seanol InsideTM shop (Seattle, US)2007- Completed Jeju Plant for Seanol Production2008- Seanol, the world 1st marine polyphenol approved as a NDI by US FDA (For the first time NDI approval in Korea)-Selected as a success case of a business supported by national policies of Korea2006- USD 6 million of foreign investment, RH Group- Technology industrialization fund of KRW 500 million, KDB2001- Livechem, Inc. established